— Bio-Path Holdings, Inc. (NASDAQ: BPTH) reported a net loss of $2.2 million or $0.78 share for the third quarter of 2019, vs. $0.74 per share loss expected.
— Research and development expenses decreased to $1.4 million from $2.3 million last year
— General and administrative expenses were $0.9 million during the three-month period, up 29% from last year
— Recorded cash of $15.4 million as of September 30, 2019, compared to $1.0 million at December 31, 2018
— Net cash used in operating activities was $6.1 million during the nine-month period ended September, compared to $4.8 million last year
— Recently, appointed Martina Molsbergen, chief executive officer of C14 Consulting, to the board of directors of Bio-Path
Most Popular
Key highlights from Deere & Co.’s (DE) Q4 2024 earnings results
Deere & Company (NYSE: DE) reported its fourth quarter 2024 earnings results today. Worldwide net sales and revenues decreased 28% year-over-year to $11.14 billion. Net income was $1.24 billion, or
NVDA Earnings: Nvidia Q3 profit jumps, beats estimates
NVIDIA Corporation (NASDAQ: NVDA) on Wednesday reported a sharp increase in adjusted profit and revenue for the third quarter of 2025. Earnings also topped analysts' estimates. The tech firm’s revenues
Lowe’s Companies (LOW): A few points to note about the Q3 2024 performance
Shares of Lowe’s Companies, Inc. (NYSE: LOW) rose over 1% on Wednesday. The stock has gained 8% over the past three months. The company delivered better-than-expected earnings results for the
